Biomarkers in Gingival Exudate and Blood Serum Before and After Surgical Treatment of Periodontitis
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 21
- 试验地点
- 4
- 主要终点
- Plaque Index (PLI) 3 months
研究概览
简要总结
In this clinical study, we have collected GCF at diseased teeth and at the same time drawn blood, both before and at 3, 6 and 12 months after periodontal surgical treatment. This give us the opportunity to investigate if periodontal treatment could reduce inflammatory biomarkers in the systemic circulation and if there is a co-variation between biomarkers in GCF and blood.
In part I of this study, we focus on biomarkers from blood serum in patients with periodontitis, before surgical therapy and under a healing period 12 months.
In part II, biomarkers in the locally collected GCF will be analyzed together with clinically reported measurements and compared with biomarkers in blood serum.
Hypothesis are
- Periodontal treatment followed by clinical healing and periodontal health will be associated a change/ reduction in biomarkers in GCF.
- The systemic levels of inflammatory biomarkers may show a delayed response to clinical healing. Periodontal surgical therapy may reduce circulating inflammatory biomarkers that could affect the low-grade chronic inflammation.
- There is a co-variation between inflammatory biomarkers in GCF and the systemic circulation.
详细描述
Periodontitis, a disease affecting the tissue supporting the tooth, is initiated by microbes colonizing the tooth causing an inflammation of the soft tissue around the tooth. In some sensitive individuals the inflammatory response leads to loss of jawbone, which affect the bone support of the tooth and may end up in loss of teeth. Periodontitis is the sixth most prevalent disease in the world, 40% of the population with affected jawbone support and approximately 10% of the population suffer from severe loss of the supporting jawbone at teeth. Periodontitis may be halted or resolved by removing the microbial biofilm from the teeth root and in severe cases combined with surgical treatment removing inflammatory tissue. The genetic factors explain approximately 50% of the disease, and but the etiology is in parts unclear and effective therapy in sensitive individuals is still missing.
The inflammatory response initiated by microbes leads to degradation of the tooth supporting tissues. The current view is that pro-inflammatory cytokines and prostaglandins, produced by leukocytes and cells of mesenchymal origin in the inflamed tissue are responsible for recruiting and activation of bone-resorbing cells, osteoclasts. The inflammatory biomarkers and tissue degradation products will leak out into the exudate in the gingival pocket next to the root surface. The bone resorption activity connected to changes in biomarkers levels and clinical parameters, during healing after periodontal treatment seem to be of value to study. The analysis of the local exudate (gingival crevicular fluid, GCF) could be used for predicting and monitoring periodontitis, as well as finding new targets for treatment.
Periodontitis could also have a systemic effect, as locally released inflammatory mediators might enter the systemic circulation and influence the development of inflammatory conditions such as cardiovascular disease (CVD), diabetes and rheumatoid arthritis. Earlier studies have shown that a low-grade chronic inflammation plays an important role in the pathogenies in atherosclerosis. Substances that indicate low-grade chronic inflammation in blood serum is for example levels of C-reactive protein (CRP), fibrinogen, and adhesion-molecules, and these biomarkers are related to CVD. The question is if periodontal treatment could change/reduce the systemic inflammatory burden of inflammatory biomarkers (CRP, fibrinogen, interleukins, and matrix metalloproteinases (MMP)).
We know today that there is association between oral health and CVD, but we do not know if the relationship it is of a causal nature. There are some intervention studies that indicate that the oral inflammatory burden may have a systemic effect. To better understand the role of the oral inflammation in development of atherosclerosis, it is important to study biomarkers at different timepoints both from the local sites (GCF) and the general systemic environment in blood. If there is a co-variation in levels of inflammatory biomarkers locally in the GCF and in the systemic circulation, this could be a strong indication of a more causal nature of the association, but we need more studies.
The value of the study is to better understand what drives the local disease progression in periodontitis and also increase the knowledge by which mechanism the oral inflammation could exert its systemic effect. Measuring levels of biomarkers in GCF and serum at several timepoints after treatment we may contribute with new insights in the role of inflammatory inducing molecules in periodontal disease, but also if there exists any systemic effect from locally released inflammatory mediators. The possibility that some molecules co-variate with disease progression or regression is of great value.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Sequential
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •patient with diagnosed periodontitis
- •at least three teeth with ≥ 4mm loss of bone support detected at radiograph, combined with periodontal pocket depth ≥5mm and bleeding on probing and/or pus, in two quadrants
排除标准
- •periodontal therapy the last 3 months
- •intake of antibiotic the last 3 months
- •intake of anti-inflammatory drug the last 2 weeks before collection of samples
结局指标
主要结局
Plaque Index (PLI) 3 months
时间窗: between baseline and 3 months after treatment
Change in PLI
Plaque Index (PLI) 6 months
时间窗: between baseline and 6 months after treatment
Change in PLI
Periodontal pocket depth (PPD) 3 months
时间窗: between baseline and 3 months after treatment
Change in PPD
Periodontal pocket depth (PPD) 6 months
时间窗: between baseline and 6 months after treatment
Change in PPD
Periodontal pocket depth (PPD) 12 months
时间窗: between baseline and 12 months after treatment
Change in PPD
Biomarkers in gingival crevicular fluid (GCF) 6 months
时间窗: between baseline and 6 months after treatment
Change in GCF protein profile using Inflammation panel (92 proteins) by Olink Bioscience.
Bleeding on probing (BOP) 12 months
时间窗: between baseline and 12 months after treatment
Change in BOP
Biomarkers in gingival crevicular fluid (GCF) 3 months
时间窗: between baseline and 3 months after treatment
Change in GCF protein profile using Inflammation panel (92 proteins) by Olink Bioscience.
Bleeding on probing (BOP) 3 months
时间窗: between baseline and 3 months after treatment
Change in BOP
Bleeding on probing (BOP) 6 months
时间窗: between baseline and 6 months after treatment
Change in BOP
Biomarkers in blood serum 3 months
时间窗: between baseline and 3 months after treatment
Change in serum protein profile using Inflammation panel (92 proteins) by Olink Bioscience plus V-PLEX Vascular Injury Panel 2 Human Kit to assess concentration of CRP, ICAM-1, SAA and VCAM-1.
Biomarkers in gingival crevicular fluid (GCF) 12 months
时间窗: between baseline and 12 months after treatment
Change in GCF protein profile using Inflammation panel (92 proteins) by Olink Bioscience.
Plaque Index (PLI) 12 months
时间窗: between baseline and 12 months after treatment
Change in PLI
Biomarkers in blood serum 6 months
时间窗: between baseline and 6 months after treatment
Change in serum protein profile using Inflammation panel (92 proteins) by Olink Bioscience plus V-PLEX Vascular Injury Panel 2 Human Kit to assess concentration of CRP, ICAM-1, SAA and VCAM-1.
Biomarkers in blood serum 12 months
时间窗: between baseline and 12 months after treatment
Change in serum protein profile using Inflammation panel (92 proteins) by Olink Bioscience plus V-PLEX Vascular Injury Panel 2 Human Kit to assess concentration of CRP, ICAM-1, SAA and VCAM-1.
次要结局
- Association between PPD and serum protein profile 12 months(between baseline and 12 months after treatment)
- Association between BOP and serum protein profile 3 months(between baseline and 3 months after treatment)
- Association between BOP and serum protein profile 6 months(between baseline and 6 months after treatment)
- Association between BOP and serum protein profile 12 months(between baseline and 12 months after treatment)
- Association between PPD and serum protein profile 3 months(between baseline and 3 months after treatment)
- Association between BOP and GCF protein profile 12 months(between baseline and 12 months after treatment)
- Association between PPD and GCF protein profile 12 months(between baseline and 12 months after treatment)
- Association between PPD and serum protein profile 6 months(between baseline and 6 months after treatment)
- Association between BOP and GCF protein profile 3 months(between baseline and 3 months after treatment)
- Association between BOP and GCF protein profile 6 months(between baseline and 6 months after treatment)
- Association between PPD and GCF protein profile 6 months(between baseline and 6 months after treatment)
- Association between PPD and GCF protein profile 3 months(between baseline and 3 months after treatment)
研究者
Anders Holmlund
Primary Investigator, Associated Professor
Region Gävleborg
